Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282680 | 0.89 | TDP1 (0.48) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL26977894 | 0.88 | NQO2 (0.52) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL2061145 | 0.85 | NPC1 (0.54) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL27276236 | 0.84 | NPC1 (0.45) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL283204 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2AMEN1NPSR1KCNA5 | |
| SCHEMBL2381485 | 0.81 | KCNA5 (0.49) | NQO2KCNA5KDM4AALDH1A1LMNA | |
| SCHEMBL27477065 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL6674887 | 0.81 | NPC1 (0.43) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL2061925 | 0.81 | NPC1 (0.47) | SMN1; SMN2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL283205 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2AMEN1NPSR1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369471-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2017-12-28 | — | — | US | disclosed |
| CN-107445940-A | Quinzolone derivatives as 5 substitutions of antitumor agent | 细胞基因公司 | 2017-12-08 | — | — | CN | disclosed |
| EP-3239144-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS | Celgene Corporation (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9732064-B2 | 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-2420498-B1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2428513-B1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2420497-B1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORP (US) | 2015-12-16 | — | — | EP | disclosed |
| US-20150080419-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-8921385-B2 | 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2066656-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORP (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2428513-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2420497-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420498-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION. | 2010-04-15 | — | — | US | disclosed |
| US-7635700-B2 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2066656-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION | 2008-07-03 | — | — | US | disclosed |
| WO-2008039489-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080419-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | SMN1; SMN2 4610/4885KMT2A 4830/4885NPC1 1307/4885 |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | FGF2, TNF, FGF1 | SMN1; SMN2 1188/4885KMT2A 4212/4885NPC1 2164/4885 |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | SMN1; SMN2 4610/4885KMT2A 4830/4885NPC1 1307/4885 |
| US-20170369471-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | SMN1; SMN2 4610/4885KMT2A 4830/4885NPC1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.